MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...

When implementing the ExoDx™ Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician's recommendation to defer prostate biopsy when the test was ...

NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer. Massive Bio, Veterans Prostate Cancer Awareness and ...

SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the ...

While prostate cancer affects one in eight men, early detection and advanced treatment options mean patients are living longer, healthier lives after diagnosis, according to the American Cancer ...

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...

As prostate cancer progresses, tumors lose the androgen receptor (AR) on which initial treatment is based. Oftentimes, such patients also lose expression prostate-specific membrane antigen (PSMA), ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...